- Croda reported first-quarter sales amounting to GBP 442 million.
- Overall sales increased by 8% compared to previous periods.
- Sales growth at constant exchange rates stood at 9%.
- Consumer Care division recorded sales of GBP 255 million.
- Life Sciences division achieved sales of GBP 134 million.
- Analyst recommendations for Croda consist of 6 buys, 8 holds, and 1 sell.
A look at Croda International Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 2 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Croda International is positioned for a positive long-term outlook. With a strong dividend score of 4, investors can expect consistent returns in the form of dividends. The company also scores well in resilience and momentum, indicating stability and potential for growth. While the value and growth scores are moderate, the overall outlook for Croda International remains promising.
Croda International plc is a leading holding company in the chemical industry, specializing in the manufacturing of various chemicals for a wide range of industries. With a diverse product portfolio that includes oleochemicals and industrial chemicals, Croda serves key sectors such as personal care, pharmaceuticals, food processing, and automotive. The company’s Smartkarma Smart Scores reflect its solid foundation and potential for sustained performance in the long run.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
